Why Is Moderna Stock Trading Lower On Wednesday?
Why Is Moderna Stock Trading Lower On Wednesday?
The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines.
美國疾病控制和預防中心的免疫實踐諮詢委員會將在本週舉行會議，以考慮和建議哪些人應該接種呼吸道合胞病毒（RSV），流感和COVID-19疫苗。
In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up.
Moderna Inc.（納斯達克代碼：MRNA）向美國機構提交的演示文稿中分享了安全性數據，截至2024年3月8日，基於18.8個月的跟蹤中位數。
The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged 60 years and above.
數據顯示，60歲及以上年齡組的參與者接種疫苗後18個月後疫苗有效性降至約50％。
Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms.
接種2個或更多症狀感染的疫苗有效率爲50.3％，而接種3個或更多症狀誘發的疾病的有效率爲49.9％。
After a median of 3.7 months of follow-up, vaccine efficacy stood at 78.7% and 80.9%, respectively, falling to 62.5% and 61.1% after a median of 8.6 months.
經過3.7個月的中位數跟蹤後，疫苗有效率分別爲78.7％和80.9％，經過8.6個月的中位數跟蹤後下降至62.5％和61.1％。
Efficacy of a single dose of GSK Plc's (NYSE:GSK) Arexvy over two calendar years showed vaccine efficacy of 73.3% (W/o season covariate) and 78.6% in severe infection.
GSK Plc （紐交所：GSK） Arexvy 單劑量在兩個日曆年中的有效性表現出無季節協變量的疫苗有效率爲73.3％，在嚴重感染中爲78.6％。
Pfizer Inc's (NYSE:PFE) Abrysvo demonstrated an overall efficacy of 77.8% in the second season and 81.5% across two seasons.
輝瑞公司（紐交所：PFE）的Abrysvo在第二個季度展示了總體有效性爲77.8％，在兩個季度中則爲81.5％。
Last year, GSK's Arexvy and Pfizer's Abrysvo went head to head for adults over 60.
去年，GSK的Arexvy和輝瑞的Abrysvo爲60歲以上的成年人而展開競爭。
Reuters notes that GSK won two-thirds of the market, mostly due to its contracts with retail pharmacies, including CVS Health Inc (NYSE:CVS).
路透社指出，GSK在零售藥店，包括西維斯健康公司（紐交所：CVS）的合同的影響下，贏得了三分之二的市場份額。
Last month, Moderna Inc. (NASDAQ:MRNA) received FDA approval for its shot, mRESVIA, to protect adults aged 60 and older.
上個月，Moderna Inc.（納斯達克：MRNA）獲得FDA批准其mRESVIA疫苗可以保護60歲以上的成年人。
Earlier this year, Moderna's longer-term trial analysis revealed a faster decline in the effectiveness of its RSV vaccine.
今年早些時候，Moderna的長期試驗分析顯示其RSV疫苗的有效性下降更快。
Follow-up data from Phase 3 mRNA-1345 Trial ReSViNET suggests the vaccine efficacy is declining faster than RSV vaccines from GSK and Pfizer.
來自3期mRNA-1345試驗ReSViNET的後續數據表明，該疫苗的有效性下降速度比GSK和輝瑞的RSV疫苗快。
Pfizer secured a major contract with the U.K. to supply millions of doses of its Abrysvo respiratory syncytial virus (RSV) vaccine, edging out local pharmaceutical giant GSK.
輝瑞公司贏得了與英國簽訂的一項重要合同，爲其Abrysvo 相關的呼吸道合胞病毒（RSV）疫苗。GSK則落後，成爲地方製藥業巨頭。
This agreement includes over 3.5 million doses for older adults and more than 1.4 million doses for pregnant mothers in England and Northern Ireland over the next two years.
這筆協議對包括英格蘭和北愛爾蘭的老年人和孕婦，未來兩年內包括超過350萬劑疫苗。
Price Action: MRNA shares are down 6.98% at $128.08 at the last check on Wednesday.
根據星期三的最新數據，MRNA的股票下跌了6.98％至128.08美元。
Photo by Lutsenko_Oleksandr on Shutterstock
Photo by Lutsenko_Oleksandr on shutterstock
譯文內容由第三人軟體翻譯。